Daily Anesthesiology Research Analysis
Today’s most impactful studies span perioperative pharmacology, pain mechanisms, and ICU diagnostics. A double-blind RCT shows esketamine reduces carboprost-induced adverse reactions during cesarean delivery under combined spinal–epidural anesthesia. A mechanistic rat study implicates Brd4-driven TLR4/NF-κB neuroinflammation in chronic postsurgical pain, while a multicenter ICU cohort finds FilmArray Pneumonia+ retains excellent diagnostic accuracy but serial quantitative changes do not predict
Summary
Today’s most impactful studies span perioperative pharmacology, pain mechanisms, and ICU diagnostics. A double-blind RCT shows esketamine reduces carboprost-induced adverse reactions during cesarean delivery under combined spinal–epidural anesthesia. A mechanistic rat study implicates Brd4-driven TLR4/NF-κB neuroinflammation in chronic postsurgical pain, while a multicenter ICU cohort finds FilmArray Pneumonia+ retains excellent diagnostic accuracy but serial quantitative changes do not predict clinical success.
Research Themes
- Perioperative pharmacology in obstetric anesthesia
- Epigenetic and inflammatory mechanisms of chronic postsurgical pain
- Rapid molecular diagnostics and antibiotic stewardship in ICU pneumonia
Selected Articles
1. Esketamine prevents carboprost-induced adverse reactions during cesarean section under combined spinal-epidural anesthesia: a double-blind, randomized trial.
In a double-blind randomized trial of 81 parturients undergoing cesarean delivery with combined spinal–epidural anesthesia, esketamine 0.5 mg/kg IV given after delivery and before intramuscular carboprost reduced intraoperative vomiting (22.5% vs 56.1) and several adverse reactions (nausea, chest rigidity, flushed face, hypertension), while increasing tachycardia. Arterial PaO2 was higher with esketamine, and incision pain at 6 h was lower; uterine contraction pain was unchanged.
Impact: Addresses a common, clinically significant set of carboprost-induced adverse reactions during cesarean delivery and proposes a readily available intervention with measurable benefits.
Clinical Implications: Consider esketamine 0.5 mg/kg IV after delivery and before carboprost in cesarean sections under combined spinal–epidural anesthesia to reduce vomiting and other adverse effects, with vigilance for tachycardia and without expecting changes in uterine contraction pain.
Key Findings
- Esketamine reduced intraoperative vomiting (22.5% vs 56.1%; p < 0.001) compared with placebo.
- Adverse reactions including nausea, chest rigidity, flushed face, and hypertension were lower with esketamine; tachycardia was higher (45% vs 19.5%; p < 0.001).
- Arterial PaO2 was higher with esketamine (91.9 ± 5.14 vs 79.76 ± 3.96 mmHg; p < 0.001).
- Incision-site pain at 6 hours postoperatively was reduced in the esketamine group; uterine contraction pain did not differ.
Methodological Strengths
- Double-blind, randomized design with prospective registration (ChiCTR2100054985).
- Clear primary and secondary outcomes with clinically relevant endpoints.
Limitations
- Single-center trial with modest sample size (n=81), limiting generalizability and power for rare adverse events.
- Short follow-up; neonatal outcomes and maternal recovery beyond early postoperative period not reported.
Future Directions: Replicate in multicenter settings with larger samples, evaluate neonatal outcomes and maternal recovery trajectories, and explore dosing strategies balancing efficacy with tachycardia risk.
OBJECTIVES: To investigate adverse reactions to carboprost reduced by intravenous esketamine administered after childbirth via cesarean delivery with the patient under combined spinal-epidural anesthesia. METHODS: The study enrolled pregnant women aged 20-40 years, with American Society of Anesthesiologists (ASA) class II or III, and a gestational age of 37 weeks or more. These women had a scheduled cesarean section procedure with the administration of combined spinal-epidural anesthesia. Patients were randomized to receive esketamine 0.5 mg/kg (Group E) or volume-matched normal saline (Group C) immediately after fetal delivery, prior to carboprost administration (250 µg intramuscularly). The primary outcome was the incidence of vomiting during surgery. The secondary outcomes were the incidence of adverse reactions (nausea, chest rigidity, flushed face, tachycardia, cough, shivering), vital signs (HR, RR, MAP, SPO
2. Bromodomain-containing protein 4 contributes to chronic postsurgical pain via activating TLR4/NF-kappaB-dependent neuroinflammation.
In a rat model of chronic postsurgical pain, spinal Brd4 expression increased alongside activation of TLR4/NF-κB signaling and elevated proinflammatory cytokines/chemokines. The BET inhibitor JQ1 prevented pain chronification in a dose-dependent manner and suppressed TLR4 activation, NF-κB phosphorylation/translocation, and release of IL-1β, IL-6, TNF-α, CXCL1, CXCL2, and CCL2.
Impact: Reveals an epigenetic driver (Brd4) of postsurgical pain chronification and demonstrates pharmacologic reversal with a BET inhibitor, pointing to a new mechanistic target.
Clinical Implications: Suggests that BET inhibition or modulation of Brd4–TLR4/NF-κB signaling could be explored to prevent chronic postsurgical pain in high-risk patients, pending translational validation.
Key Findings
- Spinal Brd4 expression was significantly upregulated after surgical incision/retraction in rats.
- TLR4/NF-κB signaling was activated with increased release of IL-1β, IL-6, TNF-α, CXCL1, CXCL2, and CCL2.
- BET inhibitor JQ1 prevented development of chronic postsurgical pain in a dose-dependent fashion and suppressed TLR4 activation and NF-κB phosphorylation/translocation.
Methodological Strengths
- Integrated behavioral assays with molecular pathway analyses in the spinal cord.
- Pharmacologic validation using a dose–response design with a BET inhibitor (JQ1).
Limitations
- Preclinical animal model; human translation uncertain.
- JQ1 may have off-target effects; specific Brd4 targeting and cell-type resolution were not detailed in the abstract.
Future Directions: Validate Brd4 signaling in human tissues, develop selective Brd4/BET modulators with favorable safety, and design prevention trials for chronic postsurgical pain in high-risk surgical populations.
BACKGROUND: Chronic pain affects 1.5 billion individuals worldwide but remains woefully undertreated, particularly occurring in the populations undergoing surgical procedures. Increasing evidence indicates that epigenetic modifications are involved in the pathogenesis of chronic pain. This study aimed to investigate the role of bromodomain-containing protein 4 (Brd4) in chronification of pain after surgery. METHODS: Male Sprague-Dawley rats were subjected to skin/muscle incision and retraction surgery to induce chronic postsurgical pain. Nociceptive thresholds and locomotor activity were assessed. The spinal cord was collected to detect the expressions of Brd4, toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-κB) pathway, and proinflammatory cytokines and chemokines release. The BET inhibitor JQ1 was used to verify the contribution of Brd4 to chronic postsurgical pain. RESULTS: Significant upregulation of spinal Brd4 expression, accompanied by activation of the TLR4/NF-κB signaling cascade and increased release of proinflammatory mediators were presented in the rat model of chronic postsurgical pain. The BET inhibitor JQ1 prevented the development of chronic postsurgical pain in a dose-dependent manner. Moreover, JQ1 obviously suppressed the activation of TLR4 and the phosphorylation and translocation of NF-κB as well as subsequently cytokines and chemokines release, including IL-1β, IL-6, TNF-α, CXCL1, CXCL2 and CCL2. CONCLUSIONS: The epigenetic regulator Brd4 initiates neuroinflammation in spinal cord through activating TLR4/NF-κB signaling pathway and enhancing cytokine and chemokines release, thereby contributing to the transition to chronic postsurgical pain. JQ1 halts chronic pain development, providing a novel therapy for patients at high risk of persistent pain.
3. Assessing FilmArray Pneumonia+ panel dynamics during antibiotic treatment to predict clinical success in ICU patients with ventilated hospital-acquired pneumonia and ventilator-associated pneumonia: a multicenter prospective study.
In 93 ICU patients with VAP or ventilated HAP, FilmArray Pneumonia+ (FA-PP) maintained excellent diagnostic performance (sensitivity ~94%, specificity ~95–98%) at diagnosis and during therapy. Although FA-PP and culture bacterial loads decreased over time, serial quantitative changes did not predict clinical success.
Impact: Clarifies the role of a widely used rapid molecular panel: strong for initial diagnosis and stable under antibiotics, but not suitable for outcome prediction through serial monitoring.
Clinical Implications: Use FA-PP to expedite accurate pathogen detection and guide early therapy in VAP/vHAP. Avoid overreliance on serial FA-PP quantitative changes to predict clinical success; integrate clinical assessment and conventional markers for stewardship decisions.
Key Findings
- At diagnosis, FA-PP sensitivity was 94% (95% CI 87–97) and specificity 98% (95% CI 97–98) compared with culture.
- Diagnostic performance remained stable during antibiotic therapy with ~94% sensitivity and 95% specificity on follow-up endotracheal aspirates.
- Serial declines in FA-PP and culture quantification occurred (p < 0.0001) but did not correlate with clinical success.
- Quantitative concordance improved with higher DNA copy numbers, reaching 100% at ≥10^7 copies/ml.
Methodological Strengths
- Prospective multicenter cohort across four ICUs with predefined serial sampling schedule.
- Appropriate statistical modeling (mixed ordinal logistic regression) and head-to-head comparison with culture.
Limitations
- Modest sample size (n=93) limits power to detect outcome correlations.
- Use of endotracheal aspirates (not bronchoalveolar lavage) may affect quantitative accuracy and generalizability.
Future Directions: Evaluate composite predictive models integrating FA-PP with clinical scores and host-response biomarkers; test stewardship strategies that limit unnecessary repeat molecular testing.
BACKGROUND: Accurate microbiological documentation seems central for managing severe pneumonia. While the FilmArray METHODS: We conducted a prospective observational study across four ICUs from April 2022 to June 2024, including patients with ventilator-associated pneumonia (VAP) or ventilated hospital-acquired pneumonia (vHAP). Bacterial loads were monitored on days 0, 1, 3, 7 and 10 and 3 days after stopping antibiotics, using endotracheal aspirates (ETAs) analyzed by FA-PP and standard cultures. The main objective was to assess the correlation between quantitative changes in FA-PP results and clinical success. Quantitative changes over time were analyzed using mixed ordinal logistic regression. RESULTS: Of the 93 patients enrolled, 60.2% (n = 56) achieved clinical success, while the ICU mortality rate was 25.8% (n = 24). Although FA-PP and culture quantification results declined over time (p < 0.0001), neither method consistently correlated with clinical success (non-significant for both). At diagnosis, FA-PP showed excellent diagnostic performance compared to culture, with a sensitivity of 94% [95% CI: 87-97] and a specificity of 98% [95% CI: 97-98]. Quantitative concordance improved with higher DNA copies, from 22.9% at the culture threshold at 10⁴ DNA copies/ml in FA-PP to 100% at ≥ 10⁷ DNA copies/ml. Diagnostic performance remained stable during antibiotic treatment with 94% sensitivity and 95% specificity in follow-up ETAs. CONCLUSIONS: FA-PP provides rapid and accurate diagnostics, but repeated testing did not predict clinical outcomes during treatment, however our small sample size limited the study power.